Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 455

1.

Signal of potentially protective drug-drug interactions from spontaneous reporting systems: proceed with caution.

Antonazzo IC, Poluzzi E, Forcesi E, Salvo F, Pariente A, Marchesini G, De Ponti F, Raschi E.

Acta Diabetol. 2019 Nov 6. doi: 10.1007/s00592-019-01441-3. [Epub ahead of print] No abstract available.

PMID:
31691870
2.

The Effects of Decreasing Dietary Crude Protein on the Growth Performance, Feed Efficiency and Meat Quality of Finishing Charolais Bulls.

Cortese M, Segato S, Andrighetto I, Ughelini N, Chinello M, Schiavon E, Marchesini G.

Animals (Basel). 2019 Nov 1;9(11). pii: E906. doi: 10.3390/ani9110906.

3.

Searching food during the night: the role of video-polysomnography in the characterization of the night eating syndrome.

Loddo G, Zanardi M, Caletti MT, Mignani F, Petroni ML, Chiaro G, Marchesini G, Provini F.

Sleep Med. 2019 Dec;64:85-91. doi: 10.1016/j.sleep.2019.06.018. Epub 2019 Jul 5.

PMID:
31671328
4.

Combination of GLP-1 receptor agonists and behavioural treatment in type 2 diabetes elicits synergistic effects on body weight: A retrospective cohort study.

Petroni ML, Montesi L, Colosimo S, Caletti MT, Mazzotti A, Marchesini G.

Endocrinol Diabetes Metab. 2019 Jul 26;2(4):e00082. doi: 10.1002/edm2.82. eCollection 2019 Oct.

5.

Adipose tissue-associated cancer risk: Is it the fat around the liver, or the fat inside the liver?

Marchesini G, Petroni ML, Cortez-Pinto H.

J Hepatol. 2019 Dec;71(6):1073-1075. doi: 10.1016/j.jhep.2019.09.020. Epub 2019 Oct 3. No abstract available.

PMID:
31586595
6.

Body composition, dual-energy X-ray absorptiometry and obesity: the paradigm of fat (re)distribution.

Ponti F, Plazzi A, Guglielmi G, Marchesini G, Bazzocchi A.

BJR Case Rep. 2019 Mar 14;5(3):20170078. doi: 10.1259/bjrcr.20170078. eCollection 2019 Sep.

7.

A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe.

Lazarus JV, Ekstedt M, Marchesini G, Mullen J, Novak K, Pericàs JM, Roel E, Romero-Gómez M, Ratziu V, Tacke F, Cortez-Pinto H, Anstee QM; EASL International Liver Foundation NAFLD Policy Review Collaborators.

J Hepatol. 2019 Sep 10. pii: S0168-8278(19)30521-5. doi: 10.1016/j.jhep.2019.08.027. [Epub ahead of print]

8.

Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation.

Chen F, Esmaili S, Rogers G, Bugianesi E, Petta S, Marchesini G, Bayoumi A, Metwally M, Azardaryany MK, Coulter S, Choo JM, Younes R, Rosso C, Liddle C, Adams LA, Craxì A, George J, Eslam M.

Hepatology. 2019 Aug 23. doi: 10.1002/hep.30908. [Epub ahead of print]

PMID:
31442319
9.

Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients with Non-alcoholic Fatty Liver Disease.

Grimaudo S, Pipitone RM, Pennisi G, Celsa C, Cammà C, Di Marco V, Barcellona MR, Boemi R, Enea M, Giannetti A, Spatola F, Marchesini G, Craxì A, Petta S.

Clin Gastroenterol Hepatol. 2019 Aug 13. pii: S1542-3565(19)30886-9. doi: 10.1016/j.cgh.2019.08.011. [Epub ahead of print]

PMID:
31419571
10.

Dysfunctional eating in type 2 diabetes mellitus: A multicenter Italian study of socio-demographic and clinical associations.

Petroni ML, Barbanti FA, Bonadonna R, Bruno G, Caletti MT, Croci M, D'Eusebio C, Dei Cas A, Invitti C, Merlo F, Molteni A, Pontiroli A, Trento M, Veronelli A, Vigili de Kreutzenberg S, Marchesini G.

Nutr Metab Cardiovasc Dis. 2019 Sep;29(9):983-990. doi: 10.1016/j.numecd.2019.06.006. Epub 2019 Jun 19.

PMID:
31353206
11.

Referral pathways for NAFLD fibrosis in primary care - No longer a 'needle in a haystack'.

Armstrong MJ, Marchesini G.

J Hepatol. 2019 Aug;71(2):246-248. doi: 10.1016/j.jhep.2019.05.010. Epub 2019 Jun 20. No abstract available.

PMID:
31229270
12.

Effect of Short Term Intensive Lifestyle Intervention on Hepatic Steatosis Indexes in Adults with Obesity and/or Type 2 Diabetes.

Reginato E, Pippi R, Aiello C, Sbroma Tomaro E, Ranucci C, Buratta L, Bini V, Marchesini G, De Feo P, Fanelli C.

J Clin Med. 2019 Jun 14;8(6). pii: E851. doi: 10.3390/jcm8060851.

13.

Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drug-drug interactions through the FDA adverse event reporting system.

Antonazzo IC, Poluzzi E, Forcesi E, Salvo F, Pariente A, Marchesini G, De Ponti F, Raschi E.

Acta Diabetol. 2019 Jun 15. doi: 10.1007/s00592-019-01378-7. [Epub ahead of print]

PMID:
31203438
14.

Prevention and Treatment of Sarcopenic Obesity in Women.

Petroni ML, Caletti MT, Dalle Grave R, Bazzocchi A, Aparisi Gómez MP, Marchesini G.

Nutrients. 2019 Jun 8;11(6). pii: E1302. doi: 10.3390/nu11061302. Review.

15.

Dapagliflozin and cardiovascular outcomes: anything else to DECLARE?

Raschi E, Poluzzi E, Marchesini G, De Ponti F.

Expert Opin Pharmacother. 2019 Jun;20(9):1087-1090. doi: 10.1080/14656566.2019.1598970. Epub 2019 Mar 28.

PMID:
30920851
16.

A Survey of Dog Owners' Attitudes toward Treats.

Morelli G, Marchesini G, Contiero B, Fusi E, Diez M, Ricci R.

J Appl Anim Welf Sci. 2019 Feb 17:1-9. doi: 10.1080/10888705.2019.1579095. [Epub ahead of print]

PMID:
30773055
17.

Correlation between DXA and laboratory parameters in normal weight, overweight, and obese patients.

Aparisi Gómez MP, Ponti F, Mercatelli D, Gasperini C, Napoli A, Battista G, Cariani S, Marchesini G, Bazzocchi A.

Nutrition. 2019 May;61:143-150. doi: 10.1016/j.nut.2018.10.023. Epub 2018 Oct 24.

PMID:
30711863
18.

Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF).

Montagnese S, Russo FP, Amodio P, Burra P, Gasbarrini A, Loguercio C, Marchesini G, Merli M, Ponziani FR, Riggio O, Scarpignato C.

Dig Liver Dis. 2019 Feb;51(2):190-205. doi: 10.1016/j.dld.2018.11.035. Epub 2018 Dec 12.

PMID:
30606696
19.

Type 2 diabetes treatment and progression of chronic kidney disease in Italian family practice.

Ermini G, Tosetti C, Zocchi D, Mandreoli M, Caletti MT, Marchesini G; Bologna Section of the Italian College of General Practitioners and Primary Care.

J Endocrinol Invest. 2019 Jul;42(7):787-796. doi: 10.1007/s40618-018-0983-0. Epub 2018 Nov 21.

PMID:
30465248
20.

Invasive Fungal Infections in Patients with Chronic Lymphoproliferative Disorders in the Era of Target Drugs.

Facchinelli D, Marchesini G, Nadali G, Pagano L.

Mediterr J Hematol Infect Dis. 2018 Nov 1;10(1):e2018063. doi: 10.4084/MJHID.2018.063. eCollection 2018. Review.

21.

Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation.

Younossi ZM, Marchesini G, Pinto-Cortez H, Petta S.

Transplantation. 2019 Jan;103(1):22-27. doi: 10.1097/TP.0000000000002484. Review.

PMID:
30335697
22.

Patient preferences for treatment in type 2 diabetes: the Italian discrete-choice experiment analysis.

Marchesini G, Pasqualetti P, Anichini R, Caputo S, Memoli G, Ponzani P, Resi V, Rizzo M, Serviddio G, Zanette G.

Acta Diabetol. 2019 Mar;56(3):289-299. doi: 10.1007/s00592-018-1236-6. Epub 2018 Oct 10.

PMID:
30306406
23.

Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease.

Raschi E, Mazzotti A, Poluzzi E, De Ponti F, Marchesini G.

Expert Opin Pharmacother. 2018 Dec;19(17):1903-1914. doi: 10.1080/14656566.2018.1531126. Epub 2018 Oct 9. Review.

PMID:
30299993
24.

An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers.

Mazzotti A, Caletti MT, Brodosi L, Di Domizio S, Forchielli ML, Petta S, Bugianesi E, Bianchi G, Marchesini G.

J Hepatol. 2018 Nov;69(5):1155-1163. doi: 10.1016/j.jhep.2018.07.013. Epub 2018 Oct 2.

25.

The Effect of Lutein on Eye and Extra-Eye Health.

Buscemi S, Corleo D, Di Pace F, Petroni ML, Satriano A, Marchesini G.

Nutrients. 2018 Sep 18;10(9). pii: E1321. doi: 10.3390/nu10091321. Review.

26.

Long-term treatment of severe obesity: are lifestyle interventions still an option?

Petroni ML, Caletti MT, Calugi S, Dalle Grave R, Marchesini G.

Expert Rev Endocrinol Metab. 2017 Nov;12(6):391-400. doi: 10.1080/17446651.2017.1386551. Epub 2017 Oct 18.

PMID:
30063435
27.

Observational research on sodium glucose co-transporter-2 inhibitors: A real breakthrough?

Raschi E, Poluzzi E, Fadini GP, Marchesini G, De Ponti F.

Diabetes Obes Metab. 2018 Dec;20(12):2711-2723. doi: 10.1111/dom.13468. Epub 2018 Aug 14. Review.

28.

The association between weight maintenance and session-by-session diet adherence, weight loss and weight-loss satisfaction.

Calugi S, Marchesini G, El Ghoch M, Gavasso I, Dalle Grave R.

Eat Weight Disord. 2018 Jun 21. doi: 10.1007/s40519-018-0528-8. [Epub ahead of print]

PMID:
29931447
29.

Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.

Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, Colombo M, Craxi A, Crespo J, Day CP, Eguchi Y, Geier A, Kondili LA, Kroy DC, Lazarus JV, Loomba R, Manns MP, Marchesini G, Nakajima A, Negro F, Petta S, Ratziu V, Romero-Gomez M, Sanyal A, Schattenberg JM, Tacke F, Tanaka J, Trautwein C, Wei L, Zeuzem S, Razavi H.

J Hepatol. 2018 Oct;69(4):896-904. doi: 10.1016/j.jhep.2018.05.036. Epub 2018 Jun 8.

30.

Statins in liver disease: not only prevention of cardiovascular events.

Magan-Fernandez A, Rizzo M, Montalto G, Marchesini G.

Expert Rev Gastroenterol Hepatol. 2018 Aug;12(8):743-744. doi: 10.1080/17474124.2018.1477588. Epub 2018 May 24. Review. No abstract available.

PMID:
29768950
31.

Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems.

Raschi E, Poluzzi E, Salvo F, Pariente A, De Ponti F, Marchesini G, Moretti U.

Nutr Metab Cardiovasc Dis. 2018 Jun;28(6):533-542. doi: 10.1016/j.numecd.2018.02.014. Epub 2018 Mar 1. Review.

PMID:
29625780
32.

The Economic Burden of Insulin-Related Hypoglycemia in Adults with Diabetes: An Analysis from the Perspective of the Italian Healthcare System.

Parekh W, Streeton SE, Baker-Knight J, Montagnoli R, Nicoziani P, Marchesini G.

Diabetes Ther. 2018 Jun;9(3):1037-1047. doi: 10.1007/s13300-018-0418-0. Epub 2018 Mar 29.

33.

Reactive hyperemia index (RHI) and cognitive performance indexes are associated with histologic markers of liver disease in subjects with non-alcoholic fatty liver disease (NAFLD): a case control study.

Tuttolomondo A, Petta S, Casuccio A, Maida C, Corte VD, Daidone M, Di Raimondo D, Pecoraro R, Fonte R, Cirrincione A, Zafonte R, Cabibi D, Cammà C, Di Marco V, Licata A, Magliozzo F, Marchesini G, Merlino G, Craxì A, Pinto A.

Cardiovasc Diabetol. 2018 Feb 16;17(1):28. doi: 10.1186/s12933-018-0670-7.

34.

Use of rumination and activity data as health status and performance indicators in beef cattle during the early fattening period.

Marchesini G, Mottaran D, Contiero B, Schiavon E, Segato S, Garbin E, Tenti S, Andrighetto I.

Vet J. 2018 Jan;231:41-47. doi: 10.1016/j.tvjl.2017.11.013. Epub 2017 Nov 28.

35.

Expected benefits and motivation to weight loss in relation to treatment outcomes in group-based cognitive-behavior therapy of obesity.

Sasdelli AS, Petroni ML, Delli Paoli A, Collini G, Calugi S, Dalle Grave R, Marchesini G.

Eat Weight Disord. 2018 Apr;23(2):205-214. doi: 10.1007/s40519-017-0475-9. Epub 2018 Jan 24.

PMID:
29368291
36.

DXA-assessed changes in body composition in obese women following two different weight loss programs.

Ponti F, Soverini V, Plazzi A, Aparisi Gómez MP, Mercatelli D, Guglielmi G, Battista G, Marchesini G, Bazzocchi A.

Nutrition. 2018 Feb;46:13-19. doi: 10.1016/j.nut.2017.07.016. Epub 2017 Aug 3.

PMID:
29290349
37.

Study of ingredients and nutrient composition of commercially available treats for dogs.

Morelli G, Fusi E, Tenti S, Serva L, Marchesini G, Diez M, Ricci R.

Vet Rec. 2018 Mar 24;182(12):351. doi: 10.1136/vr.104489. Epub 2017 Dec 20.

PMID:
29263289
38.

Cryptogenic vs. NASH-cirrhosis: The rose exists well before its name....

Caldwell S, Marchesini G.

J Hepatol. 2018 Mar;68(3):391-392. doi: 10.1016/j.jhep.2017.12.006. Epub 2017 Dec 13. No abstract available.

PMID:
29247726
39.

Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis.

Younossi ZM, Loomba R, Anstee QM, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, Serfaty L, Negro F, Caldwell SH, Ratziu V, Corey KE, Friedman SL, Abdelmalek MF, Harrison SA, Sanyal AJ, Lavine JE, Mathurin P, Charlton MR, Goodman ZD, Chalasani NP, Kowdley KV, George J, Lindor K.

Hepatology. 2018 Jul;68(1):349-360. doi: 10.1002/hep.29721.

40.

Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Younossi ZM, Loomba R, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, Serfaty L, Negro F, Caldwell SH, Ratziu V, Corey KE, Friedman SL, Abdelmalek MF, Harrison SA, Sanyal AJ, Lavine JE, Mathurin P, Charlton MR, Chalasani NP, Anstee QM, Kowdley KV, George J, Goodman ZD, Lindor K.

Hepatology. 2018 Jul;68(1):361-371. doi: 10.1002/hep.29724.

41.

Estimating the risk of severe hypoglycemic event related to glucose-lowering treatment among Italian patients with diabetes: the HYPOTHESIS database.

Mazzi S, Ravasio R, Forlani G, Veronese G, Fabbri A, Marchesini G.

Clinicoecon Outcomes Res. 2017 Nov 21;9:711-720. doi: 10.2147/CEOR.S148368. eCollection 2017.

42.

Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems.

Raschi E, Parisotto M, Forcesi E, La Placa M, Marchesini G, De Ponti F, Poluzzi E.

Nutr Metab Cardiovasc Dis. 2017 Dec;27(12):1098-1107. doi: 10.1016/j.numecd.2017.10.008. Epub 2017 Oct 18.

PMID:
29174026
43.

Evidence-Based Medicine and the Problem of Healthy Volunteers.

Marchesini G, Marchignoli F, Petta S.

Ann Hepatol. 2017 November-December,;16(6):832-834. doi: 10.5604/01.3001.0010.5272.

44.

Corrigendum to "Coffee and tea breaks for liver health" [J Hepatol 67 (2017) 221-223].

Petta S, Marchesini G.

J Hepatol. 2017 Nov;67(5):1122. doi: 10.1016/j.jhep.2017.07.016. Epub 2017 Aug 16. No abstract available.

PMID:
28822589
45.

Sense of coherence, self-esteem, and health locus of control in subjects with type 1 diabetes mellitus with/without satisfactory metabolic control.

Nuccitelli C, Valentini A, Caletti MT, Caselli C, Mazzella N, Forlani G, Marchesini G.

J Endocrinol Invest. 2018 Mar;41(3):307-314. doi: 10.1007/s40618-017-0741-8. Epub 2017 Aug 12.

PMID:
28803346
46.

Erratum to: HBV and HCV infection in type 2 diabetes mellitus: a survey in three diabetes units in different Italian areas.

Soverini V, Persico M, Bugianesi E, Forlani G, Salamone F, Masarone M, La Mura V, Mazzotti A, Bruno A, Marchesini G.

Acta Diabetol. 2017 Sep;54(9):887. doi: 10.1007/s00592-017-1032-8. No abstract available.

PMID:
28756473
47.

Coffee and tea breaks for liver health.

Petta S, Marchesini G.

J Hepatol. 2017 Aug;67(2):221-223. doi: 10.1016/j.jhep.2017.04.014. Epub 2017 Jun 1. No abstract available. Erratum in: J Hepatol. 2017 Nov;67(5):1122.

PMID:
28578838
48.

Branched-chain amino acids for people with hepatic encephalopathy.

Gluud LL, Dam G, Les I, Marchesini G, Borre M, Aagaard NK, Vilstrup H.

Cochrane Database Syst Rev. 2017 May 18;5:CD001939. doi: 10.1002/14651858.CD001939.pub4. Review.

49.

Acute Heart Failure in the Emergency Department: the SAFE-SIMEU Epidemiological Study.

Fabbri A, Marchesini G, Carbone G, Cosentini R, Ferrari A, Chiesa M, Bertini A, Rea F; Italian Society of Emergency Medicine (SIMEU).

J Emerg Med. 2017 Aug;53(2):178-185. doi: 10.1016/j.jemermed.2017.03.030. Epub 2017 May 10.

PMID:
28501384
50.

Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment.

Hanefeld M, Arteaga JM, Leiter LA, Marchesini G, Nikonova E, Shestakova M, Stager W, Gómez-Huelgas R.

Diabetes Obes Metab. 2017 Nov;19(11):1594-1601. doi: 10.1111/dom.12986. Epub 2017 Jun 7.

Supplemental Content

Loading ...
Support Center